VolitionRx Announces New Chief Financial Officer
VolitionRx Sells First NuQ® Research Use Only Kits to Active Motif
VolitionRx Appoints Dr. Habib Skaff to Board of Directors
VolitionRx Announces First Published Data in Anticancer Research Journal
VolitionRx Extends Agreement With University Hospital Bonn to Include CE Mark Performance Evaluation
President and CEO of VolitionRx Issues Corporate Update
New VolitionRx Study Data Demonstrates NuQ(R) Assays' High Detection Rate of Prostate Cancer and the Ability to Distinguish Between Prostate and Colorectal Cancer
VolitionRx Completes $3 Million Private Placement
VolitionRx Commences First Large Clinical Trial in Collaboration With Hvidovre Hospital, Denmark
VolitionRx Presents at MicroCapClub Invitational